Polskie Radio covers FDA worries about unapproved GLP-1 products, including retatrutide, being used for weight loss before any approval.
Recap by typeshit. Full story at www.polskieradio.pl.
Reuters reports the trend among GLP-1 users is prompting calls for tighter rules on supplements sold alongside the drugs.
A pharmacist account flags two separate Class II recalls involving compounded tirzepatide. Tap through for which products are affected and why.
Health authorities in New South Wales issued a warning after a jump in hospitalisations linked to unapproved peptides sold as wellness products.
A University of Iowa chemist found no peptide in a Brooklyn corner-store vial, and another expert flagged at least 13 bacterial colonies that could cause infection.
The longevity researcher shares his take on which peptides have science behind them and which he says people should steer clear of.
European regulators flagged nonarteritic anterior ischemic optic neuropathy as a very rare possible side effect of semaglutide more than 15 months ago. Medscape looks at where things stand.
Loading…